Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...

Eneboparatide is an investigational parathyroid hormone (PTH) receptor 1 agonist. By binding to a specific conformation of the PTH receptor 1, eneboparatide is expected to restore PTH function and ...

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...

Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan. “There is significant need for new treatment options for ATTR-CM, a progressive ...

The approval in Japan is based on positive results from a Phase 3 open-label, single-arm study conducted in Japan by Alexion, AstraZeneca Rare Disease, and the positive results from the global ...